Andrew M. Kaunitz, M.D., FACOG

Andrew M. Kaunitz M.D., FACOG

Professor & Associate Chair, Department of Obstetrics and Gynecology; Medical Director, UF Health Women's Specialists - Emerson

Department: Department of Obstetrics and Gynecology
Business Phone: (904) 244-3109
Business Email: andrew.kaunitz@jax.ufl.edu

Board Certifications

  • Obstetrics and Gynecology

Clinical Profile

Specialties
  • Obstetrics and Gynecology
Interests
  • Clinical Special Interests: Contraception and menopausal medicine; general gynecology
  • Research Special Interests: Contraception; menopausal medicine

Publications

2024
"Vaginal Estrogen Use in Breast Cancer Survivors: A Systematic Review and Meta-Analysis of Recurrence and Mortality Risks".
American journal of obstetrics and gynecology.():-[DOI] 10.1016/j.ajog.2024.10.054.[PMID] 39521301.
2024
Breast cancer incidence and mortality by metabolic syndrome and obesity: The Women's Health Initiative.
Cancer.130(18):3147-3156[DOI] 10.1002/cncr.35318.[PMID] 38736319.
2024
Hormonal Medications for Genitourinary Syndrome of Menopause.
Clinical obstetrics and gynecology.67(1):68-78[DOI] 10.1097/GRF.0000000000000835.[PMID] 38032827.
2024
Methods for the induction of labor: efficacy and safety.
American journal of obstetrics and gynecology.230(3S):S669-S695[DOI] 10.1016/j.ajog.2023.02.009.[PMID] 38462252.
2024
Outpatient cervical ripening and labor induction with low-dose vaginal misoprostol reduces the interval to delivery: a systematic review and network meta-analysis.
American journal of obstetrics and gynecology.230(3S):S716-S728.e61[DOI] 10.1016/j.ajog.2022.09.043.[PMID] 38462254.
2024
Single-balloon catheter with concomitant vaginal misoprostol is the most effective strategy for labor induction: a meta-review with network meta-analysis.
American journal of obstetrics and gynecology.230(3S):S696-S715[DOI] 10.1016/j.ajog.2022.01.005.[PMID] 38462253.
2024
Water birth: a systematic review and meta-analysis of maternal and neonatal outcomes.
American journal of obstetrics and gynecology.230(3S):S961-S979.e33[DOI] 10.1016/j.ajog.2023.08.034.[PMID] 38462266.
2023
Disparities in Timeliness of Endometrial Cancer Care: A Scoping Review.
Obstetrics and gynecology.142(4):967-977[DOI] 10.1097/AOG.0000000000005338.[PMID] 37734095.
2023
Intrapartum amnioinfusion reduces meconium aspiration syndrome and improves neonatal outcomes in patients with meconium-stained fluid: a systematic review and meta-analysis.
American journal of obstetrics and gynecology.228(5S):S1179-S1191.e19[DOI] 10.1016/j.ajog.2022.07.047.[PMID] 37164492.
2023
Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms.
The Journal of clinical endocrinology and metabolism.108(11):e1448-e1449[DOI] 10.1210/clinem/dgad209.[PMID] 37097747.
2023
Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?
Circulation.147(7):597-610[DOI] 10.1161/CIRCULATIONAHA.122.061559.[PMID] 36780393.
2022
Incorporating Black women's perspectives into long-acting reversible contraception implementation.
F&S reports.3(2 Suppl):80-90[DOI] 10.1016/j.xfre.2022.02.005.[PMID] 35937447.
2022
Pooled analysis of two phase 3 trials evaluating the effects of a novel combined oral contraceptive containing estetrol/drospirenone on bleeding patterns in healthy women.
Contraception.116():29-36[DOI] 10.1016/j.contraception.2022.07.010.[PMID] 35921872.
2022
Pooled efficacy results of estetrol/drospirenone combined oral contraception phase 3 trials.
Contraception.116():37-43[DOI] 10.1016/j.contraception.2022.07.009.[PMID] 35921870.
2022
Reassuring data regarding the use of hormone therapy at menopause and risk of breast cancer.
Menopause (New York, N.Y.).29(9):1001-1004[DOI] 10.1097/GME.0000000000002057.[PMID] 35998670.
2022
Tolerability and safety of the estetrol/drospirenone combined oral contraceptive: Pooled analysis of two multicenter, open-label phase 3 trials.
Contraception.116():44-50[DOI] 10.1016/j.contraception.2022.10.004.[PMID] 36257374.
2021
A Low 50-gram, 1-hour Glucose Challenge Test Value Predicts Neonatal Birth Weight Less than the 10th Percentile: A Systematic Review and Meta-Analysis.
American journal of perinatology.38(8):841-847[DOI] 10.1055/s-0039-3402749.[PMID] 31986539.
2021
Cardiovascular disease (CVD) risk scores, age, or years since menopause to predict cardiovascular disease in the Women's Health Initiative.
Menopause (New York, N.Y.).28(6):610-618[DOI] 10.1097/GME.0000000000001753.[PMID] 33950030.
2021
Efficacy, safety, and tolerability of a levonorgestrel/ethinyl estradiol transdermal delivery system: Phase 3 clinical trial results.
Contraception.103(3):137-143[DOI] 10.1016/j.contraception.2020.11.011.[PMID] 33259782.
2021
Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results.
Contraception.104(3):222-228[DOI] 10.1016/j.contraception.2021.05.002.[PMID] 34000251.
2021
Genital powder use and risk of uterine cancer: A pooled analysis of prospective studies.
International journal of cancer.148(11):2692-2701[DOI] 10.1002/ijc.33470.[PMID] 33433939.
2021
Hormonal Contraception: Systemic Estrogen and Progestin Preparations.
Clinical obstetrics and gynecology.64(4):721-738[DOI] 10.1097/GRF.0000000000000634.[PMID] 34668886.
2021
Maintaining cognitive function in surgically menopausal women: the importance of estrogen.
Menopause (New York, N.Y.).28(4):349-351[DOI] 10.1097/GME.0000000000001743.[PMID] 33570874.
2021
Pregnancy outcomes associated with an abnormal 50-g glucose screen during pregnancy: a systematic review and Meta-analysis.
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.34(24):4132-4140[DOI] 10.1080/14767058.2019.1706473.[PMID] 31893960.
2021
Risks of Testosterone for Postmenopausal Women.
Endocrinology and metabolism clinics of North America.50(1):139-150[DOI] 10.1016/j.ecl.2020.10.007.[PMID] 33518182.
2021
Segesterone acetate serum levels with a regression model of continuous use of the segesterone acetate/ethinyl estradiol contraceptive vaginal system.
Contraception.104(3):229-234[DOI] 10.1016/j.contraception.2021.03.024.[PMID] 33785318.
2021
Treatment of Women After Bilateral Salpingo-oophorectomy Performed Prior to Natural Menopause.
JAMA.326(14):1429-1430[DOI] 10.1001/jama.2021.3305.[PMID] 34636868.
2020
17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial.
Menopause (New York, N.Y.).27(12):1382-1387[DOI] 10.1097/GME.0000000000001615.[PMID] 32740481.
2020
Association of Powder Use in the Genital Area With Risk of Ovarian Cancer.
JAMA.323(1):49-59[DOI] 10.1001/jama.2019.20079.[PMID] 31910280.
2020
Best Practices for Counseling Adolescents about the Etonogestrel Implant.
Journal of pediatric and adolescent gynecology.33(5):448-454[DOI] 10.1016/j.jpag.2020.06.022.[PMID] 32621879.
2020
Does umbilical cord milking increase the risk of severe intraventricular hemorrhage in extreme preterm neonates? A multitreatment comparison.
American journal of obstetrics and gynecology.223(4):590-592[DOI] 10.1016/j.ajog.2020.06.043.[PMID] 32593537.
2020
Hormone therapy and sarcopenia: implications for the prevention of frailty as women age.
Menopause (New York, N.Y.).27(5):496-497[DOI] 10.1097/GME.0000000000001541.[PMID] 32187132.
2020
In Reply.
Menopause (New York, N.Y.).27(9):1097-1098[DOI] 10.1097/GME.0000000000001625.[PMID] 32852466.
2020
Intercepting Endometrial Cancer: Opportunities to Expand Access Using New Technology.
Cancer prevention research (Philadelphia, Pa.).13(7):563-568[DOI] 10.1158/1940-6207.CAPR-19-0556.[PMID] 32047026.
2020
Serial Bone Density Measurement and Incident Fracture Risk Discrimination in Postmenopausal Women.
JAMA internal medicine.180(9):1232-1240[DOI] 10.1001/jamainternmed.2020.2986.[PMID] 32730575.
2020
Surgical menopause: health implications and hormonal management.
Menopause (New York, N.Y.).28(1):1-3[DOI] 10.1097/GME.0000000000001680.[PMID] 33048864.
2020
The National Academies of Science, Engineering, and Medicine (NASEM) Report on Compounded Bioidentical Hormone Therapy.
Menopause (New York, N.Y.).27(11):1199-1201[DOI] 10.1097/GME.0000000000001672.[PMID] 33110032.
2020
The Women's Health Initiative trials of menopausal hormone therapy: lessons learned.
Menopause (New York, N.Y.).27(8):918-928[DOI] 10.1097/GME.0000000000001553.[PMID] 32345788.
2020
TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial.
Menopause (New York, N.Y.).27(11):1236-1241[DOI] 10.1097/GME.0000000000001602.[PMID] 33110039.
2019
Abnormal Uterine Bleeding in Reproductive-Age Women.
JAMA.321(21):2126-2127[DOI] 10.1001/jama.2019.5248.[PMID] 31070673.
2019
Associations of a Healthy Lifestyle Index With the Risks of Endometrial and Ovarian Cancer Among Women in the Women's Health Initiative Study.
American journal of epidemiology.188(2):261-273[DOI] 10.1093/aje/kwy249.[PMID] 30407487.
2019
Breast Cancer and the Obstetrician-Gynecologist: A Focus on Screening, Risk Assessment and Treatment of Survivors With Genitourinary Syndrome of Menopause.
Clinical obstetrics and gynecology.62(4):634-643[DOI] 10.1097/GRF.0000000000000479.[PMID] 31259841.
2019
Can initial vaginal bleeding patterns in etonogestrel implant users predict subsequent bleeding in the first 2 years of use?
Contraception.100(4):264-268[DOI] 10.1016/j.contraception.2019.05.017.[PMID] 31176688.
2019
Early onset of action with a 17β-estradiol, softgel, vaginal insert for treating vulvar and vaginal atrophy and moderate to severe dyspareunia.
Menopause (New York, N.Y.).26(11):1259-1264[DOI] 10.1097/GME.0000000000001394.[PMID] 31688572.
2019
Effects of ospemifene on genitourinary health assessed by prospective vulvar-vestibular photography and vaginal/vulvar health indices.
Menopause (New York, N.Y.).26(9):994-1001[DOI] 10.1097/GME.0000000000001350.[PMID] 31453961.
2019
Global Consensus Position Statement on the Use of Testosterone Therapy for Women.
The Journal of clinical endocrinology and metabolism.104(10):4660-4666[DOI] 10.1210/jc.2019-01603.[PMID] 31498871.
2019
Global Consensus Position Statement on the Use of Testosterone Therapy for Women.
Climacteric : the journal of the International Menopause Society.22(5):429-434[DOI] 10.1080/13697137.2019.1637079.[PMID] 31474158.
2019
Global Consensus Position Statement on the use of Testosterone Therapy for Women.
Maturitas.128():89-93[DOI] 10.1016/j.maturitas.2019.07.001.[PMID] 31484631.
2019
Global Consensus Position Statement on the Use of Testosterone Therapy for Women.
The journal of sexual medicine.16(9):1331-1337[DOI] 10.1016/j.jsxm.2019.07.012.[PMID] 31488288.
2019
Management of Menopause and the Role For Hormone Therapy.
Clinical obstetrics and gynecology.62(4):677-686[DOI] 10.1097/GRF.0000000000000487.[PMID] 31503029.
2019
Menopausal Estrogen-Alone Therapy and Health Outcomes in Women With and Without Bilateral Oophorectomy: A Randomized Trial.
Annals of internal medicine.171(6):406-414[DOI] 10.7326/M19-0274.[PMID] 31499528.
2019
Menopause Management Knowledge in Postgraduate Family Medicine, Internal Medicine, and Obstetrics and Gynecology Residents: A Cross-Sectional Survey.
Mayo Clinic proceedings.94(2):242-253[DOI] 10.1016/j.mayocp.2018.08.033.[PMID] 30711122.
2019
Metabolic and cardiovascular effects of TX-001HR in menopausal women with vasomotor symptoms.
Climacteric : the journal of the International Menopause Society.22(6):610-616[DOI] 10.1080/13697137.2019.1640197.[PMID] 31364889.
2019
Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.
Menopause (New York, N.Y.).26(5):506-512[DOI] 10.1097/GME.0000000000001271.[PMID] 30489424.
2019
Povidone-iodine 1% is the most effective vaginal antiseptic for preventing post-cesarean endometritis: a systematic review and network meta-analysis.
American journal of obstetrics and gynecology.221(3):261.e1-261.e20[DOI] 10.1016/j.ajog.2019.04.002.[PMID] 30954518.
2019
Reproductive health care across the lifecourse of the female cancer patient.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.27(1):23-32[DOI] 10.1007/s00520-018-4360-5.[PMID] 30051202.
2019
Vaginal estrogen: Underprescribed treatment for an underdiagnosed condition of menopausal women.
Maturitas.121():83-85[DOI] 10.1016/j.maturitas.2018.08.001.[PMID] 30098845.
2019
Women harmed by vaginal laser for treatment of GSM-the latest casualties of fear and confusion surrounding hormone therapy.
Menopause (New York, N.Y.).26(4):338-340[DOI] 10.1097/GME.0000000000001313.[PMID] 30789455.
2018
A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial.
Obstetrics and gynecology.132(1):161-170[DOI] 10.1097/AOG.0000000000002645.[PMID] 29889748.
2018
Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study.
Menopause (New York, N.Y.).25(1):11-20[DOI] 10.1097/GME.0000000000000956.[PMID] 28816933.
2018
Concern about US Preventive Services Task Force recommendation on hormone therapy for the primary prevention of chronic conditions in postmenopausal women.
Menopause (New York, N.Y.).25(5):476-[DOI] 10.1097/GME.0000000000001100.[PMID] 29658911.
2018
Contraception for midlife women: a review.
Menopause (New York, N.Y.).25(7):817-827[DOI] 10.1097/GME.0000000000001073.[PMID] 29462093.
2018
Extended Use of Systemic Menopausal Hormone Therapy.
Clinical obstetrics and gynecology.61(3):517-522[DOI] 10.1097/GRF.0000000000000382.[PMID] 29781874.
2018
Foreword: Managing Menopause by Combining Evidence With Clinical Judgment.
Clinical obstetrics and gynecology.61(3):417-418[DOI] 10.1097/GRF.0000000000000387.[PMID] 29889666.
2018
Hormonal contraception and risk of breast cancer: a closer look.
Menopause (New York, N.Y.).25(5):477-479[DOI] 10.1097/GME.0000000000001101.[PMID] 29557848.
2018
Improvement in sleep outcomes with a 17β-estradiol-progesterone oral capsule (TX-001HR) for postmenopausal women.
Menopause (New York, N.Y.).26(6):622-628[DOI] 10.1097/GME.0000000000001278.[PMID] 30586005.
2018
Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health.
Menopause (New York, N.Y.).25(6):596-608[DOI] 10.1097/GME.0000000000001121.[PMID] 29762200.
2018
Not time to abandon use of local vaginal hormone therapies.
Menopause (New York, N.Y.).25(8):855-858[DOI] 10.1097/GME.0000000000001142.[PMID] 29894370.
2018
Screening mammography for average-risk women.
Menopause (New York, N.Y.).25(3):343-345[DOI] 10.1097/GME.0000000000001026.[PMID] 29257034.
2018
Vasomotor symptoms and the risk of incident venous thrombosis in postmenopausal women.
Journal of thrombosis and haemostasis : JTH.16(5):886-892[DOI] 10.1111/jth.13993.[PMID] 29504242.
2017
A systematic review and meta-analysis of hypocalciuria in pre-eclampsia.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.138(1):3-11[DOI] 10.1002/ijgo.12165.[PMID] 28369876.
2017
Comparison of clinical outcomes among users of oral and transdermal estrogen therapy in the Women's Health Initiative Observational Study.
Menopause (New York, N.Y.).24(10):1145-1153[DOI] 10.1097/GME.0000000000000899.[PMID] 28697036.
2017
Contraceptive Considerations for Women with Gastrointestinal Disorders.
Digestive diseases and sciences.62(1):54-63[DOI] 10.1007/s10620-016-4383-z.[PMID] 27885460.
2017
Long-acting reversible contraception: an important solution to reduce unintended pregnancy.
American journal of obstetrics and gynecology.216(5):539-[DOI] 10.1016/j.ajog.2017.03.004.[PMID] 28284931.
2017
Menopausal hormone therapy and national time trends in mortality: cautions regarding causal inference.
Menopause (New York, N.Y.).24(8):874-876[DOI] 10.1097/GME.0000000000000886.[PMID] 28486245.
2017
The 2017 Hormone Therapy Position Statement of the North American Menopause Society
Menopause-the Journal of the North American Menopause Society.24(7):728-753[DOI] 10.1097/GME.0000000000000921.[PMID] .
2017
The cross-sectional association between vasomotor symptoms and hemostatic parameter levels in postmenopausal women.
Menopause (New York, N.Y.).24(4):360-370[DOI] 10.1097/GME.0000000000000777.[PMID] 27922933.
2017
The US etonogestrel implant mandatory clinical training and active monitoring programs: 6-year experience.
Contraception.95(2):205-210[DOI] 10.1016/j.contraception.2016.07.012.[PMID] 27452317.
2017
Vaginal estrogen in the treatment of genitourinary syndrome of menopause and risk of endometrial cancer: an assessment of recent studies provides reassurance.
Menopause (New York, N.Y.).24(12):1329-1332[DOI] 10.1097/GME.0000000000000996.[PMID] 29040220.
2016
An Open Letter to the Food and Drug Administration Regarding the Use of Morcellation Procedures in Women Having Surgery for Presumed Uterine Myomas.
Journal of minimally invasive gynecology.23(3):303-8[DOI] 10.1016/j.jmig.2015.12.012.[PMID] 26773577.
2016
Clinical trials of new treatments for menopausal conditions: paying attention to race.
Menopause (New York, N.Y.).23(6):589-90[DOI] 10.1097/GME.0000000000000637.[PMID] 27070806.
2016
Extended regimen combined oral contraception: A review of evolving concepts and acceptance by women and clinicians.
The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.21(2):106-15[DOI] 10.3109/13625187.2015.1107894.[PMID] 26572318.
2016
In Reply.
Obstetrics and gynecology.127(5):966-967[DOI] 10.1097/AOG.0000000000001416.[PMID] 27101114.
2016
Menopause Management--Getting Clinical Care Back on Track.
The New England journal of medicine.374(9):803-6[DOI] 10.1056/NEJMp1514242.[PMID] 26962899.
2016
Single abnormal value on 3-hour oral glucose tolerance test during pregnancy is associated with adverse maternal and neonatal outcomes: a systematic review and metaanalysis.
American journal of obstetrics and gynecology.215(3):287-97[DOI] 10.1016/j.ajog.2016.04.040.[PMID] 27133007.
2016
Stopping systemic menopausal hormone therapy: Why, when and how.
Maturitas.89():3-4[DOI] 10.1016/j.maturitas.2016.03.020.[PMID] 27180152.
2016
U.S. Food and Drug Administration's Guidance Regarding Morcellation of Leiomyomas: Well-Intentioned, But Is It Harmful for Women?
Obstetrics and gynecology.127(1):18-22[DOI] 10.1097/AOG.0000000000001157.[PMID] 26646134.
2016
Use of systemic hormone therapy in BRCA mutation carriers.
Menopause (New York, N.Y.).23(9):1026-7[DOI] 10.1097/GME.0000000000000724.[PMID] 27504919.
2015
Algorithm and mobile app for menopausal symptom management and hormonal/non-hormonal therapy decision making: a clinical decision-support tool from The North American Menopause Society.
Menopause (New York, N.Y.).22(3):247-53[DOI] 10.1097/GME.0000000000000373.[PMID] 25314150.
2015
Antenatal exposure to indomethacin increases the risk of severe intraventricular hemorrhage, necrotizing enterocolitis, and periventricular leukomalacia: a systematic review with metaanalysis.
American journal of obstetrics and gynecology.212(4):505.e1-13[DOI] 10.1016/j.ajog.2014.10.1091.[PMID] 25448524.
2015
Balancing the efficacy and safety of misoprostol: a meta-analysis comparing 25 versus 50 micrograms of intravaginal misoprostol for the induction of labour.
BJOG : an international journal of obstetrics and gynaecology.122(4):468-76[DOI] 10.1111/1471-0528.12935.[PMID] 24989790.
2015
Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials.
JAMA oncology.1(3):296-305[DOI] 10.1001/jamaoncol.2015.0494.[PMID] 26181174.
2015
Compounded bioidentical hormone therapy: time for a reality check?
Menopause (New York, N.Y.).22(9):919-20[DOI] 10.1097/GME.0000000000000484.[PMID] 26035149.
2015
Does Cervical Ripening With Foley Catheters Increase Infectious Morbidity? a Systematic Review With Meta-Analysis
Obstetrics and Gynecology.125(1):64S-[DOI] .[PMID] .
2015
Evaluation of a Transcervical Foley Catheter as a Source of Infection: A Systematic Review and Meta-analysis.
Obstetrics and gynecology.126(3):539-551[DOI] 10.1097/AOG.0000000000001002.[PMID] 26244535.
2015
Failure to treat menopausal symptoms: a disconnect between clinical practice and scientific data.
Menopause (New York, N.Y.).22(7):687-8[DOI] 10.1097/GME.0000000000000457.[PMID] 25850357.
2015
Management of Menopausal Symptoms.
Obstetrics and gynecology.126(4):859-876[DOI] 10.1097/AOG.0000000000001058.[PMID] 26348174.
2015
NAMS supports judicious use of systemic hormone therapy for women aged 65 years and older.
Menopause (New York, N.Y.).22(7):685-6[DOI] 10.1097/GME.0000000000000491.[PMID] 26035151.
2015
New contraceptive patch wearability assessed by investigators and participants in a randomized phase 3 study.
Contraception.91(3):211-6[DOI] 10.1016/j.contraception.2014.11.013.[PMID] 25586864.
2015
Ovarian cysts: presence and persistence with use of a 13.5mg levonorgestrel-releasing intrauterine system.
Contraception.91(5):412-7[DOI] 10.1016/j.contraception.2015.01.021.[PMID] 25661510.
2015
Reply: To PMID 25448524.
American journal of obstetrics and gynecology.213(6):879-[DOI] 10.1016/j.ajog.2015.08.023.[PMID] 26283456.
2015
Risk factors for endometrial cancer in black and white women: a pooled analysis from the Epidemiology of Endometrial Cancer Consortium (E2C2).
Cancer causes & control : CCC.26(2):287-296[DOI] 10.1007/s10552-014-0510-3.[PMID] 25534916.
2015
Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women.
American journal of obstetrics and gynecology.212(3):318.e1-8[DOI] 10.1016/j.ajog.2014.09.014.[PMID] 25220709.
2015
Self-reported and verified compliance in a phase 3 clinical trial of a novel low-dose contraceptive patch and pill.
Contraception.91(3):204-10[DOI] 10.1016/j.contraception.2014.11.011.[PMID] 25582984.
2014
Cervical and vaginal flora specimens are highly concordant with respect to bacterial vaginosis-associated organisms and commensal Lactobacillus species in women of reproductive age.
Journal of clinical microbiology.52(8):3078-81[DOI] 10.1128/JCM.00795-14.[PMID] 24899020.
2014
Comment on 'practical advice for avoidance of pain associated with insertion of intrauterine contraceptives': authors' response.
The journal of family planning and reproductive health care.40(2):152-3[DOI] 10.1136/jfprhc-2014-100874.[PMID] 24648536.
2014
Comment on 'Practical advice for avoidance of pain associated with insertion of intrauterine contraceptives': authors' response.
The journal of family planning and reproductive health care.40(3):235-[DOI] 10.1136/jfprhc-2014-100925.[PMID] 24939488.
2014
Comment On `Practical Advice for Avoidance of Pain Associated With Insertion of Intrauterine Contraceptives': Authors' Response
Journal of Family Planning and Reproductive Health Care.40(2):152-U82[DOI] 10.1136/jfprhc-2013-100848.[PMID] 24648535.
2014
Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause.
Menopause (New York, N.Y.).21(10):1082-90[DOI] 10.1097/GME.0000000000000210.[PMID] 24552977.
2014
Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptive.
Contraception.89(4):299-306[DOI] 10.1016/j.contraception.2014.01.013.[PMID] 24576794.
2014
Extended duration use of menopausal hormone therapy.
Menopause (New York, N.Y.).21(6):679-81[DOI] 10.1097/GME.0000000000000175.[PMID] 24398408.
2014
Global fee prohibits postpartum provision of the most effective reversible contraceptives.
Contraception.90(5):466-7[DOI] 10.1016/j.contraception.2014.08.005.[PMID] 25212061.
2014
Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women's Health Initiative Observational Study.
Menopause (New York, N.Y.).21(3):260-6[DOI] 10.1097/GME.0b013e31829a64f9.[PMID] 24045672.
2014
In reply.
Obstetrics and gynecology.123(5):1107-1108[DOI] 10.1097/AOG.0000000000000248.[PMID] 24785870.
2014
Injectable contraception: issues and opportunities.
Contraception.89(5):331-4[DOI] 10.1016/j.contraception.2014.03.014.[PMID] 24767245.
2014
Long-Term Issues in Hormone Therapy Management
Menopause-the Journal of the North American Menopause Society.21(12):1322-[DOI] .[PMID] .
2014
Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial.
BJOG : an international journal of obstetrics and gynaecology.121(6):700-5; discussion 705[DOI] 10.1111/1471-0528.12598.[PMID] 24533510.
2014
Low-dose levonorgestrel and ethinyl estradiol patch and pill: a randomized controlled trial.
Obstetrics and gynecology.123(2 Pt 1):295-303[DOI] 10.1097/AOG.0000000000000095.[PMID] 24402597.
2014
Paroxetine 7.5 Mg Reduces Daily Frequency and Severity of Vasomotor Symptoms (Vms) Associated With Menopause: Results From 2 Multicenter, Randomized, Double-Blind, Controlled Phase 3 Studies
Journal of Womens Health.23(4):17-[DOI] .[PMID] .
2014
Practical advice for avoidance of pain associated with insertion of intrauterine contraceptives.
The journal of family planning and reproductive health care.40(1):54-60[DOI] 10.1136/jfprhc-2013-100636.[PMID] 24076534.
2014
The Association Between Vasomotor Symptoms and Hemostatic Factors in Postmenopausal Women
Menopause-the Journal of the North American Menopause Society.21(12):1332-1333[DOI] .[PMID] .
2014
The short-term prediction of preterm birth: a systematic review and diagnostic metaanalysis.
American journal of obstetrics and gynecology.210(1):54.e1-54.e10[DOI] 10.1016/j.ajog.2013.09.004.[PMID] 24021995.
2014
Why the product labeling for low-dose vaginal estrogen should be changed.
Menopause (New York, N.Y.).21(9):911-6[DOI] 10.1097/GME.0000000000000316.[PMID] 25140698.
2013
Bleeding Profile of a Novel Ascending-Dose, Extended-Regimen Ethinyl Estradiol/Levonorgestrel Combination Oral Contraceptive (Oc)
Contraception.88():311-312[DOI] .[PMID] .
2013
Comment on journal review of 'Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture'.
The journal of family planning and reproductive health care.39(4):306-[DOI] 10.1136/jfprhc-2013-100759.[PMID] 24062508.
2013
Contraception in women over 40 years of age.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.185(7):565-73[DOI] 10.1503/cmaj.121280.[PMID] 23460635.
2013
Hormonal and intrauterine contraception for women aged 40 years and older.
Women's health (London, England).9(5):421-4[DOI] 10.2217/whe.13.38.[PMID] 24007246.
2013
Impact On Body Weight and Sexual Function During Treatment of Vasomotor Symptoms (Vms) Due To Menopause With Low-Dose Mesylate Salt of Paroxetine (Ldmp)
Menopause-the Journal of the North American Menopause Society.20(12):1320-[DOI] .[PMID] .
2013
Impact On Body Weight and Sexual Function During Treatment of Vasomotor Symptoms (Vms) Due To Menopause With Low-Dose Mesylate Salt of Paroxetine (Ldmp)
Menopause-the Journal of the North American Menopause Society.20(12):1320-[DOI] .[PMID] .
2013
Is Uterine Leiomyomata Associated With Postmenopausal Bleeding? a Retrospective Review
Menopause-the Journal of the North American Menopause Society.20(12):1334-[DOI] .[PMID] .
2013
Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy.
Obstetrics and gynecology.121(1):172-6[DOI] .[PMID] 23262943.
2013
Low-Dose Mesylate Salt of Paroxetine (Ldmp) Reduced Daily Frequency and Severity of Vasomotor Symptoms (Vms) Due To Menopause
Menopause-the Journal of the North American Menopause Society.20(12):1340-1341[DOI] .[PMID] .
2013
Low-Dose Mesylate Salt of Paroxetine (Ldmp) Reduced Daily Frequency of Moderate Vasomotor Symptoms (Vms) and Severe Vms Due To Menopause
Menopause-the Journal of the North American Menopause Society.20(12):1340-[DOI] .[PMID] .
2013
Low-Dose Mesylate Salt of Paroxetine (Ldmp) Reduced Daily Frequency of Moderate Vasomotor Symptoms (Vms) and Severe Vms Due To Menopause
Menopause-the Journal of the North American Menopause Society.20(12):1340-[DOI] .[PMID] .
2013
Low-Dose Mesylate Salt of Paroxetine (Ldmp) Reduced Patient Burden of Menopausal Vasomotor Symptoms
Menopause-the Journal of the North American Menopause Society.20(12):1348-[DOI] .[PMID] .
2013
Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials.
Menopause (New York, N.Y.).20(10):1027-35[DOI] 10.1097/GME.0b013e3182a66aa7.[PMID] 24045678.
2013
Management of pain associated with the insertion of intrauterine contraceptives.
Human reproduction update.19(4):419-27[DOI] 10.1093/humupd/dmt022.[PMID] 23670222.
2013
Should new-onset arthralgia be considered a menopausal symptom?
Menopause (New York, N.Y.).20(6):591-3[DOI] 10.1097/GME.0b013e31828a6a3d.[PMID] 23549444.
2013
Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism.
The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.18(3):143-7[DOI] 10.3109/13625187.2013.792637.[PMID] 23578274.
2013
Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism.
The journal of family planning and reproductive health care.39(3):156-9[DOI] 10.1136/jfprhc-2013-100624.[PMID] 23585363.
2013
The levonorgestrel intrauterine system: effective non-surgical treatment for heavy menstrual bleeding.
Evidence-based medicine.18(6):e57-[DOI] 10.1136/eb-2013-101275.[PMID] 23635841.
2013
The protein-to-creatinine ratio for the prediction of significant proteinuria in patients at risk for preeclampsia: a meta-analysis.
Annals of clinical and laboratory science.43(2):211-20[DOI] .[PMID] 23694798.
2013
Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture.
Obstetrics and gynecology.121(3):593-600[DOI] 10.1097/AOG.0b013e318283d1a1.[PMID] 23635623.
2012
Disparity in menopausal hormone therapy use between women obstetrician gynecologists and women overall: are obstetrician gynecologists underserving their patients?
Menopause (New York, N.Y.).19(10):1070-1[DOI] .[PMID] 22929036.
2012
Efficacy, safety, and tolerability of a monophasic oral contraceptive containing nomegestrol acetate and 17β-estradiol: a randomized controlled trial.
Obstetrics and gynecology.119(5):989-99[DOI] 10.1097/AOG.0b013e318250c3a0.[PMID] 22525910.
2012
Increased Compliance Independent of Patient Demographics With a Low-Dose Combination Contraceptive Patch (Ag200-15) Compared With a Low-Dose Combination Oral Contraceptive in a Phase 3 Clinical Trial
Contraception.86():314-[DOI] .[PMID] .
2012
Increased Compliance Independent of Patient Demographics With a Low-Dose Combination Contraceptive Patch (Ag200-15) Compared With a Low-Dose Combination Oral Contraceptive in a Phase 3 Clinical Trial
Contraception.86():314-[DOI] .[PMID] .
2012
Increased Compliance With a Low-Dose Combination Contraceptive Patch (Ag200-15) Compared With a Low-Dose Combination Oral Contraceptive (Coc) in a Phase 3 Clinical Trial
Contraception.86():178-[DOI] .[PMID] .
2012
Levonorgestrel-releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels.
Contraception.86(5):452-7[DOI] 10.1016/j.contraception.2012.07.018.[PMID] 22959906.
2012
Study had insufficient power to investigate safety.
BMJ (Clinical research ed.).345():e8146; author reply e8164-[DOI] 10.1136/bmj.e8146.[PMID] 23208257.
2012
The 2010 North American Menopause Society Position Statement On Hormone Therapy Goes Beyond the Available Evidence Response
Menopause-the Journal of the North American Menopause Society.19(7):836-837[DOI] 10.1097/gme.0b013e31825b32ea.[PMID] .
2012
The Levonorgestrel-Releasing Intrauterine System in Heavy Menstrual Bleeding a Benefit-Risk Review
.72():193-215[DOI] .[PMID] .
2012
The levonorgestrel-releasing intrauterine system in heavy menstrual bleeding: a benefit-risk review.
Drugs.72(2):193-215[DOI] 10.2165/11598960-000000000-00000.[PMID] 22268392.
2012
Transdermal and vaginal estradiol for the treatment of menopausal symptoms: the nuts and bolts.
Menopause (New York, N.Y.).19(6):602-3[DOI] 10.1097/gme.0b013e31824c8a5a.[PMID] 22549171.
2011
Incidental diagnosis of appendiceal mucocele with vaginal ultrasonography and computed tomography.
Obstetrics and gynecology.117(2 Pt 2):479-481[DOI] 10.1097/AOG.0b013e318203ea37.[PMID] 21252796.
2011
Removing the black box warning for depot medroxyprogesterone acetate.
Contraception.84(3):212-3[DOI] 10.1016/j.contraception.2011.01.009.[PMID] 21843682.
2011
Update on hormonal contraception and bone density.
Reviews in endocrine & metabolic disorders.12(2):93-106[DOI] 10.1007/s11154-011-9180-6.[PMID] 21559817.
2010
Cycle Control With a 21-Day Compared With a 24-Day Oral Contraceptive Pill: a Randomized Controlled Trial Reply
Obstetrics and Gynecology.115(4):867-868[DOI] 10.1097/AOG.0b013e3181d7047e.[PMID] .
2010
Depot medroxyprogesterone acetate contraceptive injections and skeletal health.
Women's health (London, England).6(3):339-42[DOI] 10.2217/whe.10.17.[PMID] 20426597.
2010
Levonorgestrel-Releasing Intrauterine System Or Medroxyprogesterone for Heavy Menstrual Bleeding: a Randomized Controlled Trial Reply
Obstetrics and Gynecology.116(6):1456-[DOI] 10.1097/AOG.0b013e3181ff7331.[PMID] .
2010
Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial.
Obstetrics and gynecology.116(3):625-632[DOI] 10.1097/AOG.0b013e3181ec622b.[PMID] 20733445.
2010
The Oncogenic Potential of Endometrial Polyps: a Systematic Review and Meta-Analysis
Menopause-the Journal of the North American Menopause Society.17():1233-[DOI] .[PMID] .
2010
The oncogenic potential of endometrial polyps: a systematic review and meta-analysis.
Obstetrics and gynecology.116(5):1197-205[DOI] 10.1097/AOG.0b013e3181f74864.[PMID] 20966706.
2009
Adding low-dose estrogen to the hormone-free interval: impact on bleeding patterns in users of a 91-day extended regimen oral contraceptive.
Contraception.79(5):350-5[DOI] 10.1016/j.contraception.2008.11.011.[PMID] 19341846.
2009
An evidence-based approach to postpartum use of depot medroxyprogesterone acetate in breastfeeding women.
Contraception.80(1):4-6[DOI] 10.1016/j.contraception.2008.12.014.[PMID] 19501209.
2009
Cycle control with a 21-day compared with a 24-day oral contraceptive pill: a randomized controlled trial.
Obstetrics and gynecology.114(6):1205-1212[DOI] 10.1097/AOG.0b013e3181beab47.[PMID] 19935020.
2009
Depo-Provera and skeletal health: reviewing the evidence; developing and disseminating a consensus.
Contraception.79(3):165-6[DOI] 10.1016/j.contraception.2008.06.017.[PMID] 19185667.
2009
Diagnostic accuracy of transvaginal sonography for the diagnosis of adenomyosis: systematic review and metaanalysis.
American journal of obstetrics and gynecology.201(1):107.e1-6[DOI] 10.1016/j.ajog.2009.03.021.[PMID] 19398089.
2009
Effective herbal treatment of vasomotor symptoms--are we any closer?
Menopause (New York, N.Y.).16(3):428-9[DOI] 10.1097/gme.0b013e31819774e4.[PMID] 19169160.
2009
Ethics and referral for abortion.
American journal of obstetrics and gynecology.200(6):e9; author reply e9-10[DOI] 10.1016/j.ajog.2008.12.017.[PMID] 19286151.
2009
Fetal fibronectin as a short-term predictor of preterm birth in symptomatic patients: a meta-analysis.
Obstetrics and gynecology.114(3):631-640[DOI] 10.1097/AOG.0b013e3181b47217.[PMID] 19701045.
2009
Levonorgestrel Intrauterine System and Medroxyprogesterone Acetate for Treatment of Heavy Menstrual Bleeding
Contraception.80():212-[DOI] .[PMID] .
2009
Levonorgestrel-Releasing Intrauterine System and Endometrial Ablation in Heavy Menstrual Bleeding a Systematic Review and Meta-Analysis
Obstetrics and Gynecology.113():1104-1116[DOI] .[PMID] .
2009
Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis.
Obstetrics and gynecology.113(5):1104-1116[DOI] 10.1097/AOG.0b013e3181a1d3ce.[PMID] 19384127.
2009
Postmenopausal osteoporosis: fracture risk and prevention.
The Journal of family practice.58(11 Suppl Postmenopausal):S1-6[DOI] .[PMID] 19891943.
2009
Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials.
Fertility and sterility.91(5):1646-53[DOI] 10.1016/j.fertnstert.2008.02.140.[PMID] 18423453.
2009
Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density.
Contraception.80(1):7-17[DOI] 10.1016/j.contraception.2009.02.005.[PMID] 19501210.
2009
The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health.
Contraception.79(3):167-77[DOI] 10.1016/j.contraception.2008.10.016.[PMID] 19185668.
2009
Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy.
Menopause (New York, N.Y.).16(4):735-41[DOI] 10.1097/gme.0b013e318199e734.[PMID] 19252451.
2009
Use of hormonal contraception in adolescents: skeletal health issues.
Current opinion in obstetrics & gynecology.21(5):396-401[DOI] 10.1097/GCO.0b013e32832c9cc6.[PMID] 19491681.
2008
Bone density recovery after depot medroxyprogesterone acetate injectable contraception use.
Contraception.77(2):67-76[DOI] 10.1016/j.contraception.2007.10.005.[PMID] 18226668.
2008
Clinical practice. Hormonal contraception in women of older reproductive age.
The New England journal of medicine.358(12):1262-70[DOI] 10.1056/NEJMcp0708481.[PMID] 18354104.
2008
Depo-Provera and skeletal health: a survey of Florida obstetrics and gynecologist physicians.
Contraception.78(5):370-6[DOI] 10.1016/j.contraception.2008.07.022.[PMID] 18929733.
2008
Depot Medroxyprogesterone Acetate and Skeletal Health: a Survey of Florida Ob/Gyn Physicians
Contraception.78(2):173-[DOI] 10.1016/j.contraception.2008.04.032.[PMID] .
2008
Do mechanical methods of cervical ripening increase infectious morbidity? A systematic review.
American journal of obstetrics and gynecology.199(2):177-87; discussion 187[DOI] 10.1016/j.ajog.2008.05.005.[PMID] 18674661.
2008
Metaanalysis of Diagnostic and Prognostic Studies: the Challenge Continues - Reply
American Journal of Obstetrics and Gynecology.199(1):E16-E17[DOI] 10.1016/j.ajog.2008.02.040.[PMID] .
2007
Aromatase inhibitor therapy for uterine bleeding in a postmenopausal woman with leiomyomata.
Menopause (New York, N.Y.).14(5):941-3[DOI] .[PMID] 17667148.
2007
Cervical length and the risk of spontaneous labor at term.
Journal of perinatology : official journal of the California Perinatal Association.27(12):749-53[DOI] .[PMID] 17762846.
2007
Combined hormonal contraceptive trials: variable data collection and bleeding assessment methodologies influence study outcomes and physician perception.
Contraception.75(1):4-10[DOI] .[PMID] 17161116.
2007
Contraceptive efficacy of a novel spermicidal microbicide used with a diaphragm: a randomized controlled trial.
Obstetrics and gynecology.110(3):577-86[DOI] .[PMID] 17766603.
2007
Long-acting contraceptives in adolescents.
Current opinion in obstetrics & gynecology.19(5):453-60[DOI] .[PMID] 17885461.
2007
Long-acting hormonal contraceptives--indispensable in preventing teen pregnancy.
The Journal of adolescent health : official publication of the Society for Adolescent Medicine.40(1):1-3[DOI] .[PMID] 17185200.
2007
Pharmacy access to emergency hormonal contraception in Jacksonville, FL: a secret shopper survey.
Contraception.75(2):126-30[DOI] .[PMID] 17241842.
2007
Progestin-releasing intrauterine systems and leiomyoma.
Contraception.75(6 Suppl):S130-3[DOI] .[PMID] 17531604.
2007
Recommendations for standardization of data collection and analysis of bleeding in combined hormone contraceptive trials.
Contraception.75(1):11-5[DOI] .[PMID] 17161117.
2007
Sonographic cervical assessment to predict the success of labor induction: a systematic review with metaanalysis.
American journal of obstetrics and gynecology.197(2):186-92[DOI] .[PMID] 17689645.
2007
Use of the levonorgestrel-IUD in the treatment of menorrhagia: improving patient outcomes while reducing the need for surgical management.
Managed care interface.20(3):47-50[DOI] .[PMID] 17458481.
2006
Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation.
Contraception.74(2):90-9[DOI] .[PMID] 16860045.
2006
Depot medroxyprogesterone acetate and bone mineral density in adolescents--the Black Box Warning: a Position Paper of the Society for Adolescent Medicine.
The Journal of adolescent health : official publication of the Society for Adolescent Medicine.39(2):296-301[DOI] .[PMID] 16857545.
2006
Hormone therapy and breast cancer risk: trumping fear with facts.
Menopause (New York, N.Y.).13(2):160-3[DOI] .[PMID] 16645526.
2005
Assessing the neonatal safety of indomethacin tocolysis: a systematic review with meta-analysis.
Obstetrics and gynecology.106(1):173-9[DOI] .[PMID] 15994634.
2005
Beyond the pill: new data and options in hormonal and intrauterine contraception.
American journal of obstetrics and gynecology.192(4):998-1004[DOI] .[PMID] 15846172.
2005
Contraceptive equity and access in the United States: a 2005 update.
Contraception.71(5):317-8[DOI] .[PMID] 15854629.
2005
Depo-Provera's black box: time to reconsider?
Contraception.72(3):165-7[DOI] .[PMID] 16102548.
2005
Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial.
Obstetrics and gynecology.105(6):1389-96[DOI] .[PMID] 15932834.
2005
Maternal death caused by midgut volvulus after bariatric surgery.
American journal of obstetrics and gynecology.193(5):1748-9[DOI] .[PMID] 16260222.
2005
Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials.
Obstetrics and gynecology.105(2):273-9[DOI] .[PMID] 15684151.
2005
Sublingual misoprostol for labor induction: a randomized clinical trial.
Obstetrics and gynecology.105(2):365-71[DOI] .[PMID] 15684166.
2004
Contraceptive efficacy and safety of DMPA-SC.
Contraception.70(4):269-75[DOI] .[PMID] 15451329.
2004
Enhancing oral contraceptive success: the potential of new formulations.
American journal of obstetrics and gynecology.190(4 Suppl):S23-9[DOI] .[PMID] 15105795.
2004
Randomized trial to compare perioperative outcomes of Filshie clip vs. Pomeroy technique for postpartum and intraoperative cesarean tubal sterilization: a pilot study.
Contraception.69(4):267-70[DOI] .[PMID] 15033399.
2004
Women's and providers' attitudes toward menstrual suppression with extended use of oral contraceptives.
Contraception.70(5):359-63[DOI] .[PMID] 15504373.
2003
Clinical characteristics of patients with an abnormal clomiphene citrate challenge test.
American journal of obstetrics and gynecology.189(2):348-52; discussion 352[DOI] .[PMID] 14520190.
2003
Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial.
JAMA.290(13):1739-48[DOI] .[PMID] 14519708.
2003
Human chorionic gonadotropin in cervicovaginal secretions as a predictor of preterm delivery.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.83(2):151-7[DOI] .[PMID] 14550589.
2003
Labor induction versus expectant management for postterm pregnancies: a systematic review with meta-analysis.
Obstetrics and gynecology.101(6):1312-8[DOI] .[PMID] 12798542.
2003
Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance.
Circulation.107(9):e67-8; author reply e67[DOI] .[PMID] 12628963.
2003
Misoprostol use during the third stage of labor.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.82(2):143-52[DOI] .[PMID] 12873774.
2002
Clinical manifestations of rotavirus infection in the neonatal intensive care unit.
The Pediatric infectious disease journal.21(12):1099-105[DOI] .[PMID] 12488657.
2002
Current concepts regarding use of DMPA.
The Journal of reproductive medicine.47(9 Suppl):785-9[DOI] .[PMID] 12380407.
2002
Expectant management versus labor induction for suspected fetal macrosomia: a systematic review.
Obstetrics and gynecology.100(5 Pt 1):997-1002[DOI] .[PMID] 12423867.
2002
Gynecologic problems of the perimenopause: evaluation and treatment.
Obstetrics and gynecology clinics of North America.29(3):455-73[DOI] .[PMID] 12353668.
2002
Hormone replacement therapy: where do we go now?
The breast journal.8(6):329-31[DOI] .[PMID] 12390354.
2002
Labor induction with 25 microg versus 50 microg intravaginal misoprostol: a systematic review.
Obstetrics and gynecology.99(1):145-51[DOI] .[PMID] 11777525.
2002
Noncontraceptive health benefits of oral contraceptives.
Reviews in endocrine & metabolic disorders.3(3):277-83[DOI] .[PMID] 12215722.
2002
The effect of tablet moistening on labor induction with intravaginal misoprostol: a randomized trial.
Obstetrics and gynecology.99(6):1080-4[DOI] .[PMID] 12052603.
2002
Use of combination hormone replacement therapy in light of recent data from the Women's Health Initiative.
Medscape women's health.7(4):8-[DOI] .[PMID] 12466740.
2001
Adjunctive intravaginal metronidazole for the prevention of postcesarean endometritis: a randomized controlled trial.
Obstetrics and gynecology.98(5 Pt 1):745-50[DOI] .[PMID] 11704163.
2001
Current options for injectable contraception in the United States.
Seminars in reproductive medicine.19(4):331-7[DOI] .[PMID] 11727175.
2001
Injectable long-acting contraceptives.
Clinical obstetrics and gynecology.44(1):73-91[DOI] .[PMID] 11219248.
2001
Lunelle monthly injectable contraceptive. An effective, safe, and convenient new birth control option.
Archives of gynecology and obstetrics.265(3):119-23[DOI] .[PMID] 11561738.
2001
Oral contraceptive use in perimenopause.
American journal of obstetrics and gynecology.185(2 Suppl):S32-7[DOI] .[PMID] 11521120.
2001
Outpatient cervical ripening with intravaginal misoprostol.
Obstetrics and gynecology.97(2):325-6[DOI] .[PMID] 11271511.
2001
Route of breech delivery and maternal and neonatal outcomes.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.73(1):7-14[DOI] .[PMID] 11336715.
2001
The hormone continuum: accrual of women's health benefits.
International journal of fertility and women's medicine.46(2):60-72[DOI] .[PMID] 11374657.
2000
Bleeding patterns of women using Lunelle monthly contraceptive injections (medroxyprogesterone acetate and estradiol cypionate injectable suspension) compared with those of women using Ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol triphasic) or other oral contraceptives.
Contraception.62(6):289-95[DOI] .[PMID] 11239615.
2000
Cervical ripening and labor induction after previous cesarean delivery.
Clinical obstetrics and gynecology.43(3):513-23[DOI] .[PMID] 10949755.
2000
Efficacy, cycle control, and safety of two triphasic oral contraceptives: Cyclessa (desogestrel/ethinyl estradiol) and ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol): a randomized clinical trial.
Contraception.61(5):295-302[DOI] .[PMID] 10906499.
2000
Injectable contraception. New and existing options.
Obstetrics and gynecology clinics of North America.27(4):741-80[DOI] .[PMID] 11091987.
2000
Menstruation: choosing whether...and when.
Contraception.62(6):277-84[DOI] .[PMID] 11239613.
2000
Misoprostol for cervical ripening and labor induction: a systematic review of the literature.
Clinical obstetrics and gynecology.43(3):475-88[DOI] .[PMID] 10949752.
2000
Perinatal morbidity associated with misoprostol-induced labor.
American journal of obstetrics and gynecology.182(3):749-50[DOI] .[PMID] 10739550.
2000
Prophylactic amnioinfusion for intrapartum oligohydramnios: a meta-analysis of randomized controlled trials.
Obstetrics and gynecology.96(5 Pt 2):861-6[DOI] .[PMID] 11094242.
2000
The effect of obstetric resident gender on forceps delivery rate.
American journal of obstetrics and gynecology.182(5):1050-1[DOI] .[PMID] 10819824.
2000
Uterine rupture associated with the use of prostaglandin E1 in patients with previous cesarean delivery.
American journal of obstetrics and gynecology.182(4):990-1[DOI] .[PMID] 10764490.
1999
Cervical ripening and labor induction with a controlled-release dinoprostone vaginal insert: a meta-analysis.
Obstetrics and gynecology.94(5 Pt 2):878-83[DOI] .[PMID] 10546777.
1999
Comparative safety, efficacy, and cycle control of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic). Lunelle Study Group.
Contraception.60(4):179-87[DOI] .[PMID] 10640164.
1999
Does smoking affect efficacy of the pill? Ask the experts.
Contraceptive technology update.20(12):143-4[DOI] .[PMID] 12295560.
1999
Efficacy of maintenance therapy after acute tocolysis: a meta-analysis.
American journal of obstetrics and gynecology.181(2):484-90[DOI] .[PMID] 10454704.
1999
Long-acting hormonal contraception: assessing impact on bone density, weight, and mood.
International journal of fertility and women's medicine.44(2):110-7[DOI] .[PMID] 10338269.
1999
Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): a contraceptive method for women in the US and worldwide.
Contraception.60(4):177-8[DOI] .[PMID] 10640163.
1999
Oral contraceptive health benefits: perception versus reality.
Contraception.59(1 Suppl):29S-33S[DOI] .[PMID] 10342094.
1998
Cesarean scar pregnancy: imaging and treatment with conservative surgery.
Obstetrics and gynecology.91(5 Pt 2):838-40[DOI] .[PMID] 9572183.
1998
Devices for endometrial sampling. A comparison.
The Journal of reproductive medicine.43(3):180-4[DOI] .[PMID] 9564641.
1998
Frequent urination and Depo-Provera. Ask the experts.
Contraceptive technology update.19(12):160-1[DOI] .[PMID] 12321808.
1998
Infertility. A clinical guide for the internist.
The Medical clinics of North America.82(2):271-95[DOI] .[PMID] 9531926.
1998
Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians.
International journal of fertility and women's medicine.43(2):73-83[DOI] .[PMID] 9609206.
1998
Labor induction with prostaglandin E1 misoprostol compared with dinoprostone vaginal insert: a randomized trial.
Obstetrics and gynecology.91(3):401-5[DOI] .[PMID] 9491868.
1998
Oral contraceptive estrogen dose considerations.
Contraception.58(3 Suppl):15S-21S; quiz 66S[DOI] .[PMID] 9807688.
1997
Contraception for the adolescent patient.
International journal of fertility and women's medicine.42(1):30-8[DOI] .[PMID] 9113833.
1997
Estrogen component of OCs.
Dialogues in contraception.5(4):1-6[DOI] .[PMID] 12293158.
1997
Labor induction with intravaginal misoprostol in term premature rupture of membranes: a randomized study.
Obstetrics and gynecology.89(6):909-12[DOI] .[PMID] 9170463.
1997
Misoprostol for cervical ripening and labor induction: a meta-analysis.
Obstetrics and gynecology.89(4):633-42[DOI] .[PMID] 9083326.
1997
Oral administration of misoprostol for labor induction: a randomized controlled trial.
Obstetrics and gynecology.90(1):153-4[DOI] .[PMID] 9207832.
1997
Randomized trial of two doses of the prostaglandin E1 analog misoprostol for labor induction.
American journal of obstetrics and gynecology.177(2):364-9; discussion 369[DOI] .[PMID] 9290452.
1997
Reappearance of the intrauterine device: a 'user-friendly' contraceptive.
International journal of fertility and women's medicine.42(2):120-7[DOI] .[PMID] 9160223.
1997
The role of androgens in menopausal hormonal replacement.
Endocrinology and metabolism clinics of North America.26(2):391-7[DOI] .[PMID] 9193891.
1996
Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer.
The Journal of reproductive medicine.41(5 Suppl):419-27[DOI] .[PMID] 8725705.
1996
Long-acting contraceptive options.
International journal of fertility and menopausal studies.41(2):69-76[DOI] .[PMID] 8829701.
1996
Randomized trial of oxytocin alone and with propranolol in the management of dysfunctional labor.
Obstetrics and gynecology.88(4 Pt 1):517-20[DOI] .[PMID] 8841209.
1995
A trial of labor complicated by uterine rupture following amnioinfusion.
Southern medical journal.88(8):847-8[DOI] .[PMID] 7631213.
1995
Calcium supplementation in mild preeclampsia remote from term: a randomized double-blind clinical trial.
Obstetrics and gynecology.85(6):915-8[DOI] .[PMID] 7770260.
1995
Contraception. A clinical review for the internist.
The Medical clinics of North America.79(6):1377-409[DOI] .[PMID] 7475496.
1995
Labor induction in patients with previous cesarean section.
American journal of perinatology.12(6):450-4[DOI] .[PMID] 8579661.
1995
Preinduction cervical ripening with commercially available prostaglandin E2 gel: a randomized, double-blind comparison with a hospital-compounded preparation.
American journal of obstetrics and gynecology.173(4):1079-84[DOI] .[PMID] 7485297.
1995
Pyelonephritis in pregnancy: once-a-day ceftriaxone versus multiple doses of cefazolin. A randomized, double-blind trial.
American journal of obstetrics and gynecology.172(1 Pt 1):129-33[DOI] .[PMID] 7847521.
1994
Cesarean section rates in teaching hospitals: a national survey.
Birth (Berkeley, Calif.).21(4):194-6[DOI] .[PMID] 7857465.
1994
Intravaginal misoprostol versus dinoprostone as cervical ripening and labor-inducing agents.
Obstetrics and gynecology.83(5 Pt 1):799-801[DOI] .[PMID] 8164948.
1994
Long-acting injectable contraception with depot medroxyprogesterone acetate.
American journal of obstetrics and gynecology.170(5 Pt 2):1543-9[DOI] .[PMID] 8178904.
1994
Prevention of pregnancy-induced hypertension by calcium supplementation in angiotensin II-sensitive patients.
Obstetrics and gynecology.84(3):349-53[DOI] .[PMID] 8058229.
1994
Resident research in obstetrics and gynecology.
The Journal of reproductive medicine.39(8):635-8[DOI] .[PMID] 7996529.
1993
ARHP launches Depo-Provera education program.
Health and sexuality.3(3):18, 24-[DOI] .[PMID] 12286568.
1993
Combined oral contraception with desogestrel/ethinyl estradiol: tolerability profile.
American journal of obstetrics and gynecology.168(3 Pt 2):1028-33[DOI] .[PMID] 8447356.
1993
Injectable contraception with depot medroxyprogesterone acetate. Current status.
Drugs.45(6):857-865[DOI] 10.2165/00003495-199345060-00001.[PMID] 7691495.
1993
Labor induction with the prostaglandin E1 methyl analogue misoprostol versus oxytocin: a randomized trial.
Obstetrics and gynecology.81(3):332-6[DOI] .[PMID] 8437780.
1992
Detection of cervical Chlamydia trachomatis and Neisseria gonorrhoeae with deoxyribonucleic acid probe assays in obstetric patients.
American journal of obstetrics and gynecology.167(3):588-91[DOI] .[PMID] 1530008.
1992
Hygroscopic cervical dilators and prostaglandin E2 gel for preinduction cervical ripening. A randomized, prospective comparison.
The Journal of reproductive medicine.37(4):355-9[DOI] .[PMID] 1593561.
1992
Injectable contraception: the USA perspective.
IPPF medical bulletin.26(6):1-3[DOI] .[PMID] 12346920.
1992
Oral contraceptives and gynecologic cancer: an update for the 1990s.
American journal of obstetrics and gynecology.167(4 Pt 2):1171-6[DOI] .[PMID] 1415442.
1991
Calcium excretion in preeclampsia.
Obstetrics and gynecology.77(4):510-3[DOI] .[PMID] 2002971.
1990
Pseudotumor cerebri following eclampsia.
European neurology.30(1):6-8[DOI] .[PMID] 2298229.
1990
Reducing cesarean sections at a teaching hospital.
American journal of obstetrics and gynecology.163(3):1081-7; discussion 1087[DOI] .[PMID] 2403133.
1989
Injectable contraception.
Clinical obstetrics and gynecology.32(2):356-68[DOI] .[PMID] 2525977.
1988
Comparison of endometrial biopsy with the endometrial Pipelle and Vabra aspirator.
The Journal of reproductive medicine.33(5):427-31[DOI] .[PMID] 3385697.
1988
Successful pregnancy after previous conservative treatment of an advanced cervical pregnancy.
Obstetrics and gynecology.71(6 Pt 2):1023-5[DOI] .[PMID] 3287250.
1987
A physician's guide to adoption.
JAMA.258(24):3537-41[DOI] .[PMID] 3316728.
1987
Prenatal care and HIV screening.
JAMA.258(19):2693-4[DOI] .[PMID] 3669236.
1986
Maternal mortality in women aged 35 years or older: United States.
JAMA.255(1):53-7[DOI] .[PMID] 3940305.
1986
Mental retardation: a controversial indication for hysterectomy.
Obstetrics and gynecology.68(3):436-8[DOI] .[PMID] 3737068.
1985
Abortions that fail.
Obstetrics and gynecology.66(4):533-7[DOI] .[PMID] 4047543.
1985
Causes of maternal mortality in the United States.
Obstetrics and gynecology.65(5):605-12[DOI] .[PMID] 3982738.
1984
Maternal deaths in the United States by size of hospital.
Obstetrics and gynecology.64(3):311-4[DOI] .[PMID] 6462559.
1984
Maternal mortality surveillance, 1974-1978.
MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.33(1):5SS-8SS[DOI] .[PMID] 6433176.
1984
Outcome of out-of-hospital births should not be measured by birth weight.
Public health reports (Washington, D.C. : 1974).99(5):435-436[DOI] .[PMID] 19313434.
1984
Perinatal and maternal mortality in a religious group avoiding obstetric care.
American journal of obstetrics and gynecology.150(7):826-31[DOI] .[PMID] 6507508.
1984
Progestogens, estrogen therapy, and endometrial cancer.
Annals of internal medicine.100(2):316-[DOI] .[PMID] 6691683.
1984
The Faith Assembly: a study of perinatal and maternal mortality.
Indiana medicine : the journal of the Indiana State Medical Association.77(3):180-3[DOI] .[PMID] 6707460.
1983
Abortion surveillance, 1979-1980.
MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.32(2):1SS-7SS[DOI] .[PMID] 6621605.
1982
Point of law: what are the legal implications of prescribing and administering FDA-approved drugs in nonapproved ways?
The Hospital medical staff.11(2):15-8[DOI] .[PMID] 10254209.
1980
Estrogen use in postmenopausal women.
The New England journal of medicine.303(25):1477-8[DOI] .[PMID] 7432409.
1979
Needle tract endometriosis: an unusual complication of amniocentesis.
Obstetrics and gynecology.54(6):753-5[DOI] .[PMID] 160025.

Office Information

Academic Office
3rd Floor, LRC
653-1 West 8th Street, L17
Jacksonville, FL 32209
(904) 244-3109
andrew.kaunitz@jax.ufl.edu
Senior Medical Secretary
Kobe Harrell
(904) 244-3109
kobe.harrell@jax.ufl.edu

Education

Medical Degree
1978 · Columbia University College of Physicians And Surgeons, New York, NY, USA
Obstetrics and Gynecology Residency
1982 · Northwestern Memorial Hospital, Chicago, IL, USA